Fusion Protein Or Fusion Polypeptide (i.e., Expression Product Of Gene Fusion) Patents (Class 424/192.1)
  • Patent number: 9765361
    Abstract: Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: September 19, 2017
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Yannick Doyon, Jeffrey C. Miller
  • Patent number: 9764007
    Abstract: The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: September 19, 2017
    Assignee: Ansun Biopharma, Inc.
    Inventors: Fang Fang, Michael P. Malakhov
  • Patent number: 9731000
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: August 15, 2017
    Assignee: Novavax, Inc.
    Inventors: Peter M. Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
  • Patent number: 9724395
    Abstract: The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the methods involve administering a composition comprising therapeutically effective amount of at least one immune stimulator to the subject. In some embodiments, a combination of at least two immune stimulators is used for the treatment. In some embodiments, the combination includes an alpha thymosin peptide and an additional immune stimulator, and/or optionally one or more additional anti-cancer agents.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: August 8, 2017
    Assignee: SciClone Pharmaceuticals, Inc.
    Inventors: Robert S. King, Cynthia W. Tuthill, Friedhelm Blobel
  • Patent number: 9717786
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: August 1, 2017
    Assignee: Novavax, Inc.
    Inventors: Peter M. Pushko, Yingyun Wu, Michael J Massare, Ye Liu, Gale Smith, Bin Zhou
  • Patent number: 9701714
    Abstract: The present invention provides compositions and methods for regulating arterial tone based on the discovery herein of novel expression and regulation of hemoglobin alpha and cytochrome B5 reductase 3 and the effects on NO and NOS.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: July 11, 2017
    Assignee: University of Virginia Patent Foundation
    Inventors: Benjamin M. Gaston, Adam C. Straub, Brant E. Isakson, Linda Columbus
  • Patent number: 9700613
    Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: July 11, 2017
    Assignee: Zoetis Services LLC
    Inventors: André Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, François Madec
  • Patent number: 9683031
    Abstract: The present invention relates to the diagnosis of autoimmune disorders, more specifically to the diagnosis of rheumatoid disorders, chronic autoimmune arthritis and even more specifically to the diagnosis of rheumatoid arthritis. A biomarker panel is provided which can be used to detect if a subject has rheumatoid arthritis. Also described are methods of identification of such biomarkers.
    Type: Grant
    Filed: March 23, 2009
    Date of Patent: June 20, 2017
    Assignee: UNIVERSITEIT HASSELT
    Inventors: Veerle Somers, Klaartje Somers, Pieter Stinissen
  • Patent number: 9623082
    Abstract: The application provides new compositions and methods for stimulating the production of natural killer (NK) cells in a subject. NK cells can be selectively expanded with a combination of stimulating ligands. Methods and compositions for the administration of stimulatory ligands modified to self-insert into tumor cells, thereby stimulating an increase in the number of NK cells in proximity to a tumor, are also described.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: April 18, 2017
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Alicja Copik, Vijay Reddy, Jeremiah Oyer
  • Patent number: 9617321
    Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: April 11, 2017
    Assignees: JOHANNES GUTENBERG-UNIVERSITAT MAINZ, BIONTECH AG
    Inventors: Thorsten Klamp, Ugur Sahin, Ozlem Tureci, Michael Koslowski, Thomas Hiller, Jens Schumacher
  • Patent number: 9593151
    Abstract: Disclosed is the use of a fusion protein in drugs for stimulating differentiation of bone marrow mesenchymal stem cells to hematopoietic stem/progenitor cells, or drugs for proliferation of granulocyte hematopoietic progenitor cells. The fusion protein has a sequence as shown in SEQ ID NO: 2 or SEQ ID NO: 4. The drugs can be used for the prevention and/or treatment of (i) hematopoietic dysfunction caused by chemotherapy, (ii) hematopoietic dysfunction caused by radiotherapy, or (iii) leukopenia.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: March 14, 2017
    Assignee: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Changsheng Liu, Wanli Xing, Jing Wang, Jiangchao Qian, Jing Liang
  • Patent number: 9580496
    Abstract: A method of preparing a canine antibody suitable for use in the therapeutic treatment of a canine is provided. In particular, there is provided immunoglobulins which can be selected for the characteristic of whether they mediate downstream complement mediated immune activation when bound to a target antigen. Canine derived antibodies comprising specific heavy chain isotypes are provided. The invention extends to the use of the immunoglobulins of the invention in methods of treating conditions such as pain, inflammatory conditions and cancerous conditions in a canine.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: February 28, 2017
    Assignee: NEXVET AUSTRALIA PTY LTD
    Inventor: David Gearing
  • Patent number: 9540425
    Abstract: The present invention relates to specific regions of the N-terminal portion of the VAR2CSA protein and to the use of such specific regions in the prevention of pregnancy-associated malaria. The invention also provides immunogenic compositions and vaccines that are useful for preventing malaria in pregnant women.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: January 10, 2017
    Assignee: INSTITUT DE RECHERCHE POUR LE DéVELOPPEMENT (IRD)
    Inventors: Nicaise Tuikue Ndam, Philippe Deloron, Sedami Ursula Alix Carine Gnidéhou, Mickaël Quiviger, Pascal Bigey, Daniel Scherman
  • Patent number: 9522180
    Abstract: The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: December 20, 2016
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Lonnie D. Shea, Stephen D. Miller, Jonathan Woon Teck Yap, Daniel R. Getts, Derrick McCarthy
  • Patent number: 9512401
    Abstract: BTLA-positive (“BTLA+”) lymphocyte signaling drives T cells and kills tumors. BTLA functions as a positive modulator of anti-tumor (anti-melanoma) T cell responses, The BTLA+ T cell responds against tumor or cancer cells, and, in cancer patients respond better to IL-2 than BTLA-negative cells. Hence, the BTLA-positive T cell in cancers is a positive marker for selection of enriched anti-tumor-cancer reactive T cells and can be used or applied for adoptive T-cell therapy or for therapeutic purposes.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: December 6, 2016
    Assignee: Board of Regents, The University of Texas System
    Inventors: Laszlo Radvanyi, Patrick Hwu, Chantale Bernatchez
  • Patent number: 9510571
    Abstract: An aim is to produce a suitable foreign protein in egg white in transgenic birds at levels equivalent to or higher than the expression levels achieved using an ovalbumin promoter or an actin promoter, and to reduce the great burden on birds by reducing the expression at sites other than the oviduct while achieving expression sufficient to predict the expression levels before the birds reach sexual maturity. Provided is a transgenic bird containing a nucleic acid base sequence in chromosome in a cell that forms the oviduct, the sequence containing: (a) an avian endoplasmic reticulum chaperone promoter; and (b) a nucleic acid base sequence encoding a suitable foreign protein, functionally linked to the promoter. Also provided is a method for producing a suitable foreign protein, including recovering the suitable foreign protein from the transgenic bird.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: December 6, 2016
    Assignee: KANEKA CORPORATION
    Inventors: Kenji Kyogoku, Hiroyuki Watanabe
  • Patent number: 9492536
    Abstract: Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked ?1 and ?1 domains, and MHC class I-based molecules that comprise covalently linked ?1 and ?2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, including treatment and/or prevention of central nervous system damage relating to stroke.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: November 15, 2016
    Assignees: Oregon Health & Science University, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Halina Offner, Patricia D. Hurn, Arthur A. Vandenbark, Gregory G. Burrows
  • Patent number: 9492525
    Abstract: The present invention relates to RSV vaccines and methods for inducing an immune response to RSV in a subject comprising administering an RSV vaccine.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: November 15, 2016
    Assignee: NANOBIO CORPORATION
    Inventors: Ali I. Fattom, Nicolas Lukacs, James R. Baker, Jr., Vira Bitko, Tarek Hamouda
  • Patent number: 9481734
    Abstract: The invention relates to antibody compositions and use of the composition to detect disease processes associated with elaboration of proteases. The reagents are directed to assessing an IgG breakdown product that is the result of such proteolytic cleavage. The invention further relates to the use of a therapeutic immunospecific for IgG protease cleavage products to restore effector function to antibody compositions that are subject to protease cleavage.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: November 1, 2016
    Assignee: Janssen Biotech, Inc.
    Inventors: Robert Jordan, David Knight, Randall Brezski, Mary Ryan, Diane Petrone
  • Patent number: 9458513
    Abstract: The present invention relates to an oligonucleotide which is designed on the basis of a nucleotide sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 and hybridizes with the endogenous plasmid gene of Chlamydia trachomatis, oligonucleotide primer and probe for detecting Chlamydia trachomatis, the detection method of Chlamydia trachomatis using said primer and probe, and a primer for detecting Chlamydia trachomatis of said oligonucleotide or the use to a probe design.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: October 4, 2016
    Assignee: WAKO PURE CHEMICAL INDUSTRIES, LTD.
    Inventors: Tomokazu Ishikawa, Hiromi Kumon
  • Patent number: 9458444
    Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: October 4, 2016
    Assignee: OPKO BIOLOGICS LTD.
    Inventors: Udi Eyal Fima, Gili Hart
  • Patent number: 9452209
    Abstract: The present invention provides an immunogenic influenza composition in a dose volume suitable for human use, comprising an influenza virus antigen or antigenic preparation thereof and an adjuvant composition comprising an oil-in-water emulsion, wherein said oil-in-water emulsion comprises a metabolisable oil at a level of below 11 mg and an emulsifying agent at a level of below 5 mg and optionally a tocol or a sterol at a level of below 12 mg. Suitably the amount of influenza antigen per strain per dose is 15 ?g HA or a low amount such as less than 15 ?g HA.
    Type: Grant
    Filed: April 15, 2008
    Date of Patent: September 27, 2016
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: William Ripley Ballou, Emmanuel Jules Hanon
  • Patent number: 9452210
    Abstract: A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plant lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: September 27, 2016
    Assignee: MEDICAGO INC.
    Inventors: Marc-Andre D'Aoust, Manon Couture, Frederic Ors, Sonia Trépanier, Pierre-Olivier Lavoie, Michele Dargis, Louis-Philippe Vézina, Nathalie Landry
  • Patent number: 9428555
    Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 16, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: August 30, 2016
    Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen University
    Inventors: Ying Gu, Shaowei Li, Minxi Wei, Yangling Xian, Wenxin Luo, Ningshao Xia
  • Patent number: 9402916
    Abstract: The invention provides an agent for preventing or treating a condition characterized by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: August 2, 2016
    Assignee: THE UNIVERSITY OF BIRMINGHAM
    Inventors: Mark Cobbold, David Millar
  • Patent number: 9399665
    Abstract: A composition for preventing or treating cervical cancer comprising a human papillomavirus plasmodium and an immunity enhancer is provided. A fusion protein including a fusion polypeptide recombined to transform a 3D structure of E6 and E7, which are antigens against types 16 and 18 human papillomavirus (HPV), a signal peptide for secreting the fusion polypeptide outside the cells and an immunity enhancer peptide present in an individual is also provided. The fusion protein may be useful in treating HPV-triggered tumors by inducing an immune response specific to the antigens against the HPV types 16 and 18.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: July 26, 2016
    Assignee: GENEXINE, Inc.
    Inventors: Young Chul Sung, Sang Hwan Seo, You Suk Suh
  • Patent number: 9399678
    Abstract: The present invention relates to polypeptides comprising one or more antibody single domains, or antigen-binding fragments thereof, directed against Tumor Necrosis Factor-alpha, in particular, two light chain variable domains in dimeric form, where the dimer has high solubility. It also relates to methods of using anti-Tumor Necrosis Factor-alpha polypeptides in treating inflammatory disorders, including rheumatoid arthritis. Compositions and methods for enhancing therapeutic potential of anti-Tumor Necrosis Factor-alpha polypeptides are provided, including linking the polypeptide to an albumin-binding domain and/or de-immunizing the polypeptide, to provide therapeutic agents with good solubility, enhanced serum half-life, and/or reduced immunogenicity, while substantially maintaining the specific binding properties of the anti-Tumor Necrosis Factor-alpha polypeptides.
    Type: Grant
    Filed: September 19, 2012
    Date of Patent: July 26, 2016
    Assignee: Technophage, Investigacao E Desenvolvimento Em Biotecnologia, SA
    Inventors: Frederico Nuno Castanheira Aires da Silva, Sofia Volker Cörte-Real, Rui Pedro da Silva Albuquerque e Freitas, Sara Ferreira Llorente Grancho Lourenço
  • Patent number: 9388225
    Abstract: The present application is related to a modified protein comprising a protein having a coiled coil domain and a peptide having the sequence such as shown in SEQ ID NO 1: ZXBBBBZ that is linked to the coiled coil domain wherein: Z is any amino acid or is absent; X is any amino acid; B is an arginine (R) or a lysine (K). Said modified protein is in particular an antigen or a carrier protein, associated to an antigen. This modified protein has an increased affinity for negatively charged polymers such as nucleic acids or heparin, and shows an increased immunogenicity.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: July 12, 2016
    Assignee: Imaxio
    Inventors: Judith Del Campo Ascarateil, Imene Turki Hani, Fergal Hill
  • Patent number: 9388221
    Abstract: The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide or protein of at least 10 amino acid residues in length having a sequence corresponding to either a sequence from the N terminal amino acids 1-200 of papillomavirus L2 protein (for cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types) or a sequence from the N terminal amino acids 1-88 of papillomavirus L2 protein (for cross-neutralizing antibodies against heterologous papillomavirus types), (b) a peptide or protein of at least 10 amino acid residues in length with at least 55% identity with the sequence from (a), or (c) a peptide or protein as defined in either (a) or (b) which is conjugated or fused to a protein o
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: July 12, 2016
    Assignees: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, The Johns Hopkins University
    Inventors: John T. Schiller, Diana V. Pastrana, Richard B. S. Roden, Ratish Gambhira, Douglas R. Lowy
  • Patent number: 9359425
    Abstract: Methods are provided for the treatment of subjects with cognitive or neuropsychiatric impairment induced by substance addiction and for increasing cognitive function in a subject with substance addiction. In some embodiments, the methods include administering to the subject a therapeutically effective amount of a major histocompatibility complex (MHC) molecule including covalently linked first, second, and third domains; wherein the first domain is an MHC class II ?1 domain and the second domain is an MHC class II ?1 domain; or wherein the first domain is an MHC class I ?1 domain and the second domain is an MHC class I ?2 domain; and wherein the third domain is covalently linked to the first domain and comprises an antigen of the central or peripheral nervous system.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: June 7, 2016
    Assignees: Oregon Health & Science University, The United States of America as Represented by the Department of Veterans Affairs
    Inventors: Arthur A. Vandenbark, Gregory G. Burrows
  • Patent number: 9358282
    Abstract: The invention provides an agent for preventing or treating a condition characterized by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: June 7, 2016
    Assignee: The University of Birmingham
    Inventors: Mark Cobbold, David Millar
  • Patent number: 9353395
    Abstract: A fusion protein of pyrroloquinoline quinone glucose dehydrogenase (PQQGDH) and a cytochrome is disclosed. PQQGDH is, for example, a water-soluble PQQGDH derived from Acinetobacter calcoaceticus. The cytochrome is, for example, an electron transfer domain of quinohemoprotein ethanol dehydrogenase from Comamonas testosteroni. The fusion protein of the present invention shows intramolecular electron transfer from PQQ, a redox center, to the cytochrome, which allow construction of a direct electron transfer-type glucose sensor which requires no electron mediators.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: May 31, 2016
    Assignees: ARKRAY, Inc., Ultizyme International Ltd.
    Inventor: Koji Sode
  • Patent number: 9321786
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 26, 2016
    Assignees: Celgene Avilomics Research, Inc., Sanofi
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson
  • Patent number: 9283268
    Abstract: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: March 15, 2016
    Assignee: Wake Forest University Health Sciences
    Inventors: Rajendar K. Deora, Meenu Mishra, Neelima Sukumar
  • Patent number: 9254317
    Abstract: Immunogenic compositions are provided herein that are useful for inducing an immune response specific against group A streptococcus (GAS). Immunogenic compositions provided herein are multivalent and comprise a plurality of immunogenic peptides or fusion polypeptides comprising the immunogenic peptides that induce an immune response against GAS. The immunogenic compositions provided herein induce an immune response against the GAS serotypes represented by an immunogenic peptide (derived from an M protein or Spa protein) comprised within the immunogenic composition and also induce an immune response against serotypes that are unrepresented by any immunogenic peptide included in the immunogenic composition. Methods for using the compositions for inducing an immune response against GAS and for treating or reducing the likelihood of occurrence of a GAS infection are also provided.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: February 9, 2016
    Assignee: University of Tennessee Research Foundation
    Inventor: James B. Dale
  • Patent number: 9249407
    Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: February 2, 2016
    Assignee: OPKO BIOLOGICS LTD.
    Inventors: Udi Eyal Fima, Gili Hart
  • Patent number: 9248171
    Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from an allograft antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or treatment of allograft rejection and in the manufacture of medicaments therefore.
    Type: Grant
    Filed: February 14, 2008
    Date of Patent: February 2, 2016
    Assignee: IMCYSE SA
    Inventor: Jean-Marie Saint-Remy
  • Patent number: 9212353
    Abstract: The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: December 15, 2015
    Assignee: Ansun Biopharma, Inc.
    Inventors: Fang Fang, Michael Malakhov
  • Patent number: 9212355
    Abstract: The present invention relates to means and methods for determining neurotoxin activity. Specifically, it relates to a polypeptide having caspase activity comprising a large subunit and a small subunit wherein the caspase further comprises a neurotoxin cleavage site which upon cleavage activates the caspase activity. Also encompassed are polynucleotides encoding the polypeptides as well as vectors or host cells comprising the polynucleotides. The present invention further relates to a method for determining neurotoxin activity in a sample based on the polypeptide of the invention as well as the use of the polypeptide for determining neurotoxin activity in a sample, in general.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: December 15, 2015
    Assignee: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Klaus Fink, Martin Vey
  • Patent number: 9187536
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: November 17, 2015
    Assignee: Wyeth LLC
    Inventors: Annaliesa Sybil Anderson, Maninder K. Sidhu, Robert G. K. Donald, Kathrin Ute Jansen, Narender K. Kalyan, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
  • Patent number: 9187751
    Abstract: The invention relates to a new adjuvant and to its use in combination with an antigen.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: November 17, 2015
    Assignee: LABORATORIOS LETI, S.L.
    Inventors: Carlos Alonso-Bedate, Manuel Soto-Alvarez, Nuria Parody-De La Fuente, Yago Pico De Coana-Suarez
  • Patent number: 9175085
    Abstract: The invention relates to methods for the temporal administration of EDA agonists, in particular EDI200, which correlate to optimal therapeutic response windows required for the formation of any EDA-dependent structures such as ectodermal appendages. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with genetic disorders, in particular, XLHED.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: November 3, 2015
    Assignee: EDIMER PHARMACEUTICALS, INC.
    Inventors: Pascal Schneider, Christine Kowalczyk
  • Patent number: 9149517
    Abstract: Embodiments of the invention are directed to methods and compositions of multitype HPV polypeptides.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: October 6, 2015
    Assignee: The Johns Hopkins University
    Inventors: Richard Roden, Subhashini Jagu
  • Patent number: 9144603
    Abstract: Disclosed are: a cell capable of expressing an exogenous GITRL or an exogenous GITRL derivative; a method for producing the cell; a therapeutic or prophylactic agent comprising the cell as an active ingredient; use of the cell in the manufacture of a therapeutic or prophylactic agent; a method comprising a step of administering the cell to a subject; a viral vector carrying a gene encoding a GITRL or a GITRL derivative; a therapeutic or prophylactic agent comprising the viral vector as an active ingredient; use of the viral vector in the manufacture of a therapeutic or prophylactic agent; and a method comprising a step of administering the viral vector to a subject.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: September 29, 2015
    Assignees: MIE UNIVERSITY, TAKARA BIO INC.
    Inventors: Hiroshi Shiku, Hiroaki Ikeda, Jun Mitsui, Yuki Takenaka, Junichi Mineno, Ikunoshin Kato
  • Patent number: 9096886
    Abstract: The present invention relates to means and methods for determining neurotoxin activity. Specifically, it relates to a polypeptide having caspase activity comprising a large subunit and a small subunit wherein the caspase further comprises a neurotoxin cleavage site which upon cleavage activates the caspase activity. Also encompassed are polynucleotides encoding the polypeptides as well as vectors or host cells comprising the polynucleotides. The present invention further relates to a method for determining neurotoxin activity in a sample based on the polypeptide of the invention as well as the use of the polypeptide for determining neurotoxin activity in a sample, in general.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: August 4, 2015
    Assignee: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Klaus Fink, Martin Vey
  • Patent number: 9080176
    Abstract: Novel double and triple fusion reporter gene constructs harboring distinct imagable reporter genes are provided, as well as applications for the use of such double and triple fusion constructs in living cells and in living animals using distinct imaging technologies.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: July 14, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Sanjiv Gambhir, Ray Pritha
  • Patent number: 9050287
    Abstract: Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV 6, HPV 11, HPV 33 and HPV58 E6 and E7. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed.
    Type: Grant
    Filed: October 12, 2011
    Date of Patent: June 9, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B Weiner, Jian Yan
  • Patent number: 9044507
    Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a viral vector antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or suppression of immune responses to viral vectors and in the manufacture of medicaments therefore.
    Type: Grant
    Filed: February 16, 2009
    Date of Patent: June 2, 2015
    Assignees: LIFE SCIENCES RESEARCH PARTNERS VZW, KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventor: Jean-Marie Saint-Remy
  • Publication number: 20150147350
    Abstract: A combination of anti-neoplastic agents that provides increased activity over monotherapy, or in some cases at least an unexpected lack of negative interaction. In particular, the drug combination that includes a MAGE-A3 immunotherapeutic, in combination with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and/or a MEK inhibitor, particularly N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethy; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof is described.
    Type: Application
    Filed: December 19, 2012
    Publication date: May 28, 2015
    Inventors: Catherine Marie Ghislaine Gerard, Sylvie Laquerre, Peter F. Lebowitz, Frederic Francois Eugene Lehmann, Jamila Louahed
  • Patent number: 9040054
    Abstract: The present invention relates to a hypoallergenic molecule consisting of Bet v Ia or an allergen having at least 40% identity to Bet v Ia comprising mutations of at least four amino acid residues in the region of amino acids 100 to 125 of Bet v Ia or its corresponding region of the allergen having at least 40% identity to Bet v 1a.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: May 26, 2015
    Assignee: BIOMAY AG
    Inventors: Michael Wallner, Barbara Bohle, Martin Himly, Nicole Wopfner, Gabriele Gadermaier, Matthias Egger, Peter Lackner, Fatima Ferreira, Michael Hauser